Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults

2015 ◽  
Vol 34 (11) ◽  
pp. 1236-1243 ◽  
Author(s):  
Roger Baxter ◽  
Yaela Baine ◽  
Devayani Kolhe ◽  
Carmen I. Baccarini ◽  
Jacqueline M. Miller ◽  
...  
Keyword(s):  
Young Adults ◽  
Single Dose ◽  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Adolescents And Young Adults ◽  
Antibody Persistence

scholarly journals 10865-year Antibody Persistence and Booster Response to a Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults

2014 ◽  
Vol 1 (suppl_1) ◽  
pp. S320-S320
Author(s):  
Roger Baxter ◽  
Yaela Baine ◽  
Devayani Kolhe ◽  
Carmen Baccarini ◽  
Jacqueline M Miller ◽  
...  
Keyword(s):  
Young Adults ◽  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Adolescents And Young Adults ◽  
Antibody Persistence

scholarly journals Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults

2010 ◽  
Vol 17 (4) ◽  
pp. 537-544 ◽  
Author(s):  
Roberto Gasparini ◽  
Michele Conversano ◽  
Gianni Bona ◽  
Giovanni Gabutti ◽  
Alessandra Anemona ◽  
...  
Keyword(s):  
Young Adults ◽  
Adverse Events ◽  
Randomized Trial ◽  
Conjugate Vaccine ◽  
Antibody Responses ◽  
Adolescents And Young Adults ◽  
Tdap Vaccine ◽  
Glycoconjugate Vaccine ◽  
Clinically Significant ◽  
Quadrivalent Meningococcal Conjugate Vaccine

ABSTRACT This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, when administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis (Tdap) vaccine, in subjects aged 11 to 25 years. Subjects received either MenACWY-CRM and Tdap, MenACWY-CRM and saline placebo, or Tdap and saline placebo. No significant increase in reactogenicity and no clinically significant vaccine-related adverse events (AEs) occurred when MenACWY-CRM and Tdap were administered concomitantly. Similar immunogenic responses to diphtheria, tetanus, and meningococcal (serogroups A, C, W-135, and Y) antigens were observed, regardless of concomitant vaccine administration. Antipertussis antibody responses were comparable between vaccine groups for filamentous hemagglutinin and were slightly lower, although not clinically significantly, for pertussis toxoid and pertactin when the two vaccines were administered concomitantly. These results indicate that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic and that it can be coadministered with Tdap to adolescents and young adults.

Sign in / Sign up

Export Citation Format

Share Document